Massive Pulmonary Embolism in a Patient with Heparin Induced Thrombocytopenia: Successful Treatment with Dabigatran/Heparin Iliskili Trombositopenili Bir Hastada Masif Pulmoner Emboli: Basarili Dabigatran Uygulamasi
Heparin induced thrombocytopenia (HIT) is a rare, potentially fatal, immune-mediated complication of heparin therapy, associated with thrombosis and thrombocytopenia. In this study, a successful dabigatran administration in a case with massive pulmonary thromboembolism (mPTE) and HIT is presented. 5...
Gespeichert in:
Veröffentlicht in: | The Eurasian journal of medicine 2016-02, Vol.48 (1), p.65 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 1 |
container_start_page | 65 |
container_title | The Eurasian journal of medicine |
container_volume | 48 |
creator | Bircan, Haci Ahmet Alanoglu, Emine Guchan |
description | Heparin induced thrombocytopenia (HIT) is a rare, potentially fatal, immune-mediated complication of heparin therapy, associated with thrombosis and thrombocytopenia. In this study, a successful dabigatran administration in a case with massive pulmonary thromboembolism (mPTE) and HIT is presented. 57 years-old female, who was receiving low molecular weight heparin (LMWH) (0.4 mL once a daily, S.C. for 11 days) due to total knee replacement, was referred to our clinic with the hypotension and syncope attacks. Her echocardiography and pulmonary CT angiography findings were consistent with mPTE. We detected a serious decrease in her platelet count highly suggestive for HIT (plt: 54 x [10.sup.3]/[micro]L). LMWH was discontinued and dabigatran was started (150 mg twice daily). After platelet count increased over 150 x [10.sup.3]/[micro]L, dabigatran was switched to warfarin. Since heparin is widely used in medicine, all physicians need to be aware of this life threatening complication of heparin. Replacing heparin with an alternative anticoagulant such as dabigatran may become a life-saving strategy especially in case of HIT complicated with mPTE. Keywords: Dabigatran, heparin, low molecular weight heparin, new oral anticoagulants, pulmonary embolism. Heparin iliskili trombositopeni (HIT), heparin tedavisinin nadir ancak olumcul olabilen immun aracili komplikasyonu olup, tromboz ve trombositopeni ile seyreder. Burada HIT ve masif pulmoner tromboemboli (mPTE) olgusunda basarili Dabigatran (oral trombin inhibitoru) uygulamasi sunulmaktadir. Total diz replasmani nedeniyle profilaktik dusuk molekuler agirlikli heparin (DMAH, 0,4 mL 1x1, S.C., 11 gun) tedavisi altinda olan 57 yasinda kadin hasta hipotansiyon ve senkop yakinmalariyla klinigimize sevk edildi. Ekokardiyografi ve pulmoner BT anjiyografi bulgulari mPTE bulgulari ile uyumlu idi. HIT tanisini dusunduren trombosit sayilarinda belirgin dusme tespit edildi (plt: 54 x [10.sup.3]/[micro]L). Aldigi DMAH ve warfarin tedavisi hemen kesilerek Dabigatran baslandi (2 x 150 mg). Trombosit sayisi 150 x [10.sup.3]/[micro]L uzerine ciktiktan sonra dabigatran warfarin ile degistirildi. Tum hekimler tipta yaygin olarak kullanilan heparinin hayati tehdit eden bu komplikasyonunu akilda tutmalidir. Heparinin dabigatran gibi alternatif bir antikoagulan ile degistirilmesi mPTE ile komplike olmus HIT olgularinda hayat kurtaran bir strateji olabilir. Anahtar Kelimeler: Dabigatran, heparin, dusuk molekuler agirlikli heparin, yeni |
doi_str_mv | 10.5152/eurasianjmed.2015.95 |
format | Article |
fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_1788512523</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A541891708</galeid><sourcerecordid>A541891708</sourcerecordid><originalsourceid>FETCH-LOGICAL-g953-ed042fd2ff1667b32e4ef7cbaad0b5a777c1ca6f24bf4b400e45740fd2457b143</originalsourceid><addsrcrecordid>eNptj0FPGzEQhVdVkYoo_6AHSz0n2F473nADShskKpAI52jWOw6T7npTe5cqv7R_h0FEoYfah7Ge3vvmuSi-KDm1yuozHBNkgrjpsJlqqex0bj8Ux6qU1aRyRn88vEvzqTjNeSP5mHlZ6tlx8fcn5EzPKO7HtusjpJ247uq-pdwJigLEPQyEcRB_aHgSC9xCYvkmNqPHRiyfUs9uvxv6LUaCc_Eweo85h7EVy4QwdIfsN6hpDUOCeHbA8Jpf1BJbXzGZ3jAsXFISC8gDNCC4IYV9P0z7eufiEjJD2PsOFo-79dhCx4HPxVGANuPpfp4Uy-_Xy6vF5Pbux83Vxe1kPbflBBtpdGh0CGo2c3Wp0WBwvgZoZG3BOeeVh1nQpg6mNlKisc5ITvCslSlPiq9v2G3qf4-Yh9WmH1PkjSvlqsoqbXX57lpDiyuKoee2vqPsVxfWqGqunKzYNf2Pi2-DHXn-eyDW_wm8AE_ioyY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1788512523</pqid></control><display><type>article</type><title>Massive Pulmonary Embolism in a Patient with Heparin Induced Thrombocytopenia: Successful Treatment with Dabigatran/Heparin Iliskili Trombositopenili Bir Hastada Masif Pulmoner Emboli: Basarili Dabigatran Uygulamasi</title><source>DOAJ Directory of Open Access Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Bircan, Haci Ahmet ; Alanoglu, Emine Guchan</creator><creatorcontrib>Bircan, Haci Ahmet ; Alanoglu, Emine Guchan</creatorcontrib><description>Heparin induced thrombocytopenia (HIT) is a rare, potentially fatal, immune-mediated complication of heparin therapy, associated with thrombosis and thrombocytopenia. In this study, a successful dabigatran administration in a case with massive pulmonary thromboembolism (mPTE) and HIT is presented. 57 years-old female, who was receiving low molecular weight heparin (LMWH) (0.4 mL once a daily, S.C. for 11 days) due to total knee replacement, was referred to our clinic with the hypotension and syncope attacks. Her echocardiography and pulmonary CT angiography findings were consistent with mPTE. We detected a serious decrease in her platelet count highly suggestive for HIT (plt: 54 x [10.sup.3]/[micro]L). LMWH was discontinued and dabigatran was started (150 mg twice daily). After platelet count increased over 150 x [10.sup.3]/[micro]L, dabigatran was switched to warfarin. Since heparin is widely used in medicine, all physicians need to be aware of this life threatening complication of heparin. Replacing heparin with an alternative anticoagulant such as dabigatran may become a life-saving strategy especially in case of HIT complicated with mPTE. Keywords: Dabigatran, heparin, low molecular weight heparin, new oral anticoagulants, pulmonary embolism. Heparin iliskili trombositopeni (HIT), heparin tedavisinin nadir ancak olumcul olabilen immun aracili komplikasyonu olup, tromboz ve trombositopeni ile seyreder. Burada HIT ve masif pulmoner tromboemboli (mPTE) olgusunda basarili Dabigatran (oral trombin inhibitoru) uygulamasi sunulmaktadir. Total diz replasmani nedeniyle profilaktik dusuk molekuler agirlikli heparin (DMAH, 0,4 mL 1x1, S.C., 11 gun) tedavisi altinda olan 57 yasinda kadin hasta hipotansiyon ve senkop yakinmalariyla klinigimize sevk edildi. Ekokardiyografi ve pulmoner BT anjiyografi bulgulari mPTE bulgulari ile uyumlu idi. HIT tanisini dusunduren trombosit sayilarinda belirgin dusme tespit edildi (plt: 54 x [10.sup.3]/[micro]L). Aldigi DMAH ve warfarin tedavisi hemen kesilerek Dabigatran baslandi (2 x 150 mg). Trombosit sayisi 150 x [10.sup.3]/[micro]L uzerine ciktiktan sonra dabigatran warfarin ile degistirildi. Tum hekimler tipta yaygin olarak kullanilan heparinin hayati tehdit eden bu komplikasyonunu akilda tutmalidir. Heparinin dabigatran gibi alternatif bir antikoagulan ile degistirilmesi mPTE ile komplike olmus HIT olgularinda hayat kurtaran bir strateji olabilir. Anahtar Kelimeler: Dabigatran, heparin, dusuk molekuler agirlikli heparin, yeni oral antikoagulanlar, pulmoner emboli.</description><identifier>ISSN: 1308-8734</identifier><identifier>EISSN: 1308-8742</identifier><identifier>DOI: 10.5152/eurasianjmed.2015.95</identifier><language>eng</language><publisher>Istanbul: AVES</publisher><subject>Anticoagulants ; Blood clots ; Blood platelets ; Complications and side effects ; Conflicts of interest ; Dosage and administration ; Drug therapy ; Embolisms ; Health aspects ; Hospital patients ; Immunoglobulins ; Laboratories ; Liver ; Low molecular weight heparin ; Molecular weight ; Mortality ; Physicians ; Practice ; Pulmonary arteries ; Pulmonary embolism ; Thrombocytopenia ; Thromboembolism ; Thrombosis</subject><ispartof>The Eurasian journal of medicine, 2016-02, Vol.48 (1), p.65</ispartof><rights>COPYRIGHT 2016 AVES</rights><rights>Copyright Aves Yayincilik Ltd. STI. Feb 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,864,27923,27924</link.rule.ids></links><search><creatorcontrib>Bircan, Haci Ahmet</creatorcontrib><creatorcontrib>Alanoglu, Emine Guchan</creatorcontrib><title>Massive Pulmonary Embolism in a Patient with Heparin Induced Thrombocytopenia: Successful Treatment with Dabigatran/Heparin Iliskili Trombositopenili Bir Hastada Masif Pulmoner Emboli: Basarili Dabigatran Uygulamasi</title><title>The Eurasian journal of medicine</title><description>Heparin induced thrombocytopenia (HIT) is a rare, potentially fatal, immune-mediated complication of heparin therapy, associated with thrombosis and thrombocytopenia. In this study, a successful dabigatran administration in a case with massive pulmonary thromboembolism (mPTE) and HIT is presented. 57 years-old female, who was receiving low molecular weight heparin (LMWH) (0.4 mL once a daily, S.C. for 11 days) due to total knee replacement, was referred to our clinic with the hypotension and syncope attacks. Her echocardiography and pulmonary CT angiography findings were consistent with mPTE. We detected a serious decrease in her platelet count highly suggestive for HIT (plt: 54 x [10.sup.3]/[micro]L). LMWH was discontinued and dabigatran was started (150 mg twice daily). After platelet count increased over 150 x [10.sup.3]/[micro]L, dabigatran was switched to warfarin. Since heparin is widely used in medicine, all physicians need to be aware of this life threatening complication of heparin. Replacing heparin with an alternative anticoagulant such as dabigatran may become a life-saving strategy especially in case of HIT complicated with mPTE. Keywords: Dabigatran, heparin, low molecular weight heparin, new oral anticoagulants, pulmonary embolism. Heparin iliskili trombositopeni (HIT), heparin tedavisinin nadir ancak olumcul olabilen immun aracili komplikasyonu olup, tromboz ve trombositopeni ile seyreder. Burada HIT ve masif pulmoner tromboemboli (mPTE) olgusunda basarili Dabigatran (oral trombin inhibitoru) uygulamasi sunulmaktadir. Total diz replasmani nedeniyle profilaktik dusuk molekuler agirlikli heparin (DMAH, 0,4 mL 1x1, S.C., 11 gun) tedavisi altinda olan 57 yasinda kadin hasta hipotansiyon ve senkop yakinmalariyla klinigimize sevk edildi. Ekokardiyografi ve pulmoner BT anjiyografi bulgulari mPTE bulgulari ile uyumlu idi. HIT tanisini dusunduren trombosit sayilarinda belirgin dusme tespit edildi (plt: 54 x [10.sup.3]/[micro]L). Aldigi DMAH ve warfarin tedavisi hemen kesilerek Dabigatran baslandi (2 x 150 mg). Trombosit sayisi 150 x [10.sup.3]/[micro]L uzerine ciktiktan sonra dabigatran warfarin ile degistirildi. Tum hekimler tipta yaygin olarak kullanilan heparinin hayati tehdit eden bu komplikasyonunu akilda tutmalidir. Heparinin dabigatran gibi alternatif bir antikoagulan ile degistirilmesi mPTE ile komplike olmus HIT olgularinda hayat kurtaran bir strateji olabilir. Anahtar Kelimeler: Dabigatran, heparin, dusuk molekuler agirlikli heparin, yeni oral antikoagulanlar, pulmoner emboli.</description><subject>Anticoagulants</subject><subject>Blood clots</subject><subject>Blood platelets</subject><subject>Complications and side effects</subject><subject>Conflicts of interest</subject><subject>Dosage and administration</subject><subject>Drug therapy</subject><subject>Embolisms</subject><subject>Health aspects</subject><subject>Hospital patients</subject><subject>Immunoglobulins</subject><subject>Laboratories</subject><subject>Liver</subject><subject>Low molecular weight heparin</subject><subject>Molecular weight</subject><subject>Mortality</subject><subject>Physicians</subject><subject>Practice</subject><subject>Pulmonary arteries</subject><subject>Pulmonary embolism</subject><subject>Thrombocytopenia</subject><subject>Thromboembolism</subject><subject>Thrombosis</subject><issn>1308-8734</issn><issn>1308-8742</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNptj0FPGzEQhVdVkYoo_6AHSz0n2F473nADShskKpAI52jWOw6T7npTe5cqv7R_h0FEoYfah7Ge3vvmuSi-KDm1yuozHBNkgrjpsJlqqex0bj8Ux6qU1aRyRn88vEvzqTjNeSP5mHlZ6tlx8fcn5EzPKO7HtusjpJ247uq-pdwJigLEPQyEcRB_aHgSC9xCYvkmNqPHRiyfUs9uvxv6LUaCc_Eweo85h7EVy4QwdIfsN6hpDUOCeHbA8Jpf1BJbXzGZ3jAsXFISC8gDNCC4IYV9P0z7eufiEjJD2PsOFo-79dhCx4HPxVGANuPpfp4Uy-_Xy6vF5Pbux83Vxe1kPbflBBtpdGh0CGo2c3Wp0WBwvgZoZG3BOeeVh1nQpg6mNlKisc5ITvCslSlPiq9v2G3qf4-Yh9WmH1PkjSvlqsoqbXX57lpDiyuKoee2vqPsVxfWqGqunKzYNf2Pi2-DHXn-eyDW_wm8AE_ioyY</recordid><startdate>20160201</startdate><enddate>20160201</enddate><creator>Bircan, Haci Ahmet</creator><creator>Alanoglu, Emine Guchan</creator><general>AVES</general><general>Galenos Publishing House</general><scope>3V.</scope><scope>7RQ</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>EDSIH</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>U9A</scope></search><sort><creationdate>20160201</creationdate><title>Massive Pulmonary Embolism in a Patient with Heparin Induced Thrombocytopenia: Successful Treatment with Dabigatran/Heparin Iliskili Trombositopenili Bir Hastada Masif Pulmoner Emboli: Basarili Dabigatran Uygulamasi</title><author>Bircan, Haci Ahmet ; Alanoglu, Emine Guchan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g953-ed042fd2ff1667b32e4ef7cbaad0b5a777c1ca6f24bf4b400e45740fd2457b143</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Anticoagulants</topic><topic>Blood clots</topic><topic>Blood platelets</topic><topic>Complications and side effects</topic><topic>Conflicts of interest</topic><topic>Dosage and administration</topic><topic>Drug therapy</topic><topic>Embolisms</topic><topic>Health aspects</topic><topic>Hospital patients</topic><topic>Immunoglobulins</topic><topic>Laboratories</topic><topic>Liver</topic><topic>Low molecular weight heparin</topic><topic>Molecular weight</topic><topic>Mortality</topic><topic>Physicians</topic><topic>Practice</topic><topic>Pulmonary arteries</topic><topic>Pulmonary embolism</topic><topic>Thrombocytopenia</topic><topic>Thromboembolism</topic><topic>Thrombosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bircan, Haci Ahmet</creatorcontrib><creatorcontrib>Alanoglu, Emine Guchan</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Career & Technical Education Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Turkey Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>The Eurasian journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bircan, Haci Ahmet</au><au>Alanoglu, Emine Guchan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Massive Pulmonary Embolism in a Patient with Heparin Induced Thrombocytopenia: Successful Treatment with Dabigatran/Heparin Iliskili Trombositopenili Bir Hastada Masif Pulmoner Emboli: Basarili Dabigatran Uygulamasi</atitle><jtitle>The Eurasian journal of medicine</jtitle><date>2016-02-01</date><risdate>2016</risdate><volume>48</volume><issue>1</issue><spage>65</spage><pages>65-</pages><issn>1308-8734</issn><eissn>1308-8742</eissn><abstract>Heparin induced thrombocytopenia (HIT) is a rare, potentially fatal, immune-mediated complication of heparin therapy, associated with thrombosis and thrombocytopenia. In this study, a successful dabigatran administration in a case with massive pulmonary thromboembolism (mPTE) and HIT is presented. 57 years-old female, who was receiving low molecular weight heparin (LMWH) (0.4 mL once a daily, S.C. for 11 days) due to total knee replacement, was referred to our clinic with the hypotension and syncope attacks. Her echocardiography and pulmonary CT angiography findings were consistent with mPTE. We detected a serious decrease in her platelet count highly suggestive for HIT (plt: 54 x [10.sup.3]/[micro]L). LMWH was discontinued and dabigatran was started (150 mg twice daily). After platelet count increased over 150 x [10.sup.3]/[micro]L, dabigatran was switched to warfarin. Since heparin is widely used in medicine, all physicians need to be aware of this life threatening complication of heparin. Replacing heparin with an alternative anticoagulant such as dabigatran may become a life-saving strategy especially in case of HIT complicated with mPTE. Keywords: Dabigatran, heparin, low molecular weight heparin, new oral anticoagulants, pulmonary embolism. Heparin iliskili trombositopeni (HIT), heparin tedavisinin nadir ancak olumcul olabilen immun aracili komplikasyonu olup, tromboz ve trombositopeni ile seyreder. Burada HIT ve masif pulmoner tromboemboli (mPTE) olgusunda basarili Dabigatran (oral trombin inhibitoru) uygulamasi sunulmaktadir. Total diz replasmani nedeniyle profilaktik dusuk molekuler agirlikli heparin (DMAH, 0,4 mL 1x1, S.C., 11 gun) tedavisi altinda olan 57 yasinda kadin hasta hipotansiyon ve senkop yakinmalariyla klinigimize sevk edildi. Ekokardiyografi ve pulmoner BT anjiyografi bulgulari mPTE bulgulari ile uyumlu idi. HIT tanisini dusunduren trombosit sayilarinda belirgin dusme tespit edildi (plt: 54 x [10.sup.3]/[micro]L). Aldigi DMAH ve warfarin tedavisi hemen kesilerek Dabigatran baslandi (2 x 150 mg). Trombosit sayisi 150 x [10.sup.3]/[micro]L uzerine ciktiktan sonra dabigatran warfarin ile degistirildi. Tum hekimler tipta yaygin olarak kullanilan heparinin hayati tehdit eden bu komplikasyonunu akilda tutmalidir. Heparinin dabigatran gibi alternatif bir antikoagulan ile degistirilmesi mPTE ile komplike olmus HIT olgularinda hayat kurtaran bir strateji olabilir. Anahtar Kelimeler: Dabigatran, heparin, dusuk molekuler agirlikli heparin, yeni oral antikoagulanlar, pulmoner emboli.</abstract><cop>Istanbul</cop><pub>AVES</pub><doi>10.5152/eurasianjmed.2015.95</doi><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1308-8734 |
ispartof | The Eurasian journal of medicine, 2016-02, Vol.48 (1), p.65 |
issn | 1308-8734 1308-8742 |
language | eng |
recordid | cdi_proquest_journals_1788512523 |
source | DOAJ Directory of Open Access Journals; PubMed Central; Alma/SFX Local Collection |
subjects | Anticoagulants Blood clots Blood platelets Complications and side effects Conflicts of interest Dosage and administration Drug therapy Embolisms Health aspects Hospital patients Immunoglobulins Laboratories Liver Low molecular weight heparin Molecular weight Mortality Physicians Practice Pulmonary arteries Pulmonary embolism Thrombocytopenia Thromboembolism Thrombosis |
title | Massive Pulmonary Embolism in a Patient with Heparin Induced Thrombocytopenia: Successful Treatment with Dabigatran/Heparin Iliskili Trombositopenili Bir Hastada Masif Pulmoner Emboli: Basarili Dabigatran Uygulamasi |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T16%3A36%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Massive%20Pulmonary%20Embolism%20in%20a%20Patient%20with%20Heparin%20Induced%20Thrombocytopenia:%20Successful%20Treatment%20with%20Dabigatran/Heparin%20Iliskili%20Trombositopenili%20Bir%20Hastada%20Masif%20Pulmoner%20Emboli:%20Basarili%20Dabigatran%20Uygulamasi&rft.jtitle=The%20Eurasian%20journal%20of%20medicine&rft.au=Bircan,%20Haci%20Ahmet&rft.date=2016-02-01&rft.volume=48&rft.issue=1&rft.spage=65&rft.pages=65-&rft.issn=1308-8734&rft.eissn=1308-8742&rft_id=info:doi/10.5152/eurasianjmed.2015.95&rft_dat=%3Cgale_proqu%3EA541891708%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1788512523&rft_id=info:pmid/&rft_galeid=A541891708&rfr_iscdi=true |